Navigation Links
BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now

HERNDON, Va., March 23 /PRNewswire-USNewswire/ -- Julian Bailes, MD, BHR Pharma, LLC's Lead Advisor for Moderate Traumatic Brain Injury (TBI) today released the following statement regarding Brain Injury Awareness Month:

"BHR Pharma salutes the Brain Injury Association of America (BIAA) for its concerted efforts to raise awareness about the dangers and proper treatment of concussions everywhere from playgrounds to professional sports arenas.  BIAA is correctly pointing out through its advocacy that concussions are TBIs, with the potential for serious, debilitating and long-term effects.  

"TBI is defined as a non-degenerative, non-congenital insult to the brain from an external mechanical force, possibly leading to temporary or permanent impairments of cognitive, physical and psychosocial functions with an associated diminished or altered state of consciousness.

"According to the Centers for Disease Control and Prevention, U.S. hospital emergency departments treat an estimated 3.8 million sports- and recreation-related concussions annually.  It is time that athletes of all ages and their coaches completely move away from 'play through pain' attitudes in relation to concussions.  

"During Brain Injury Awareness Month, it is also important to recognize that traumatic brain injuries range from concussions to severe head trauma, such as injuries sustained in traffic accidents – a leading cause of TBI in the world, accounting for 40-50 percent of hospitalizations.  Approximately 1.7 million Americans per year suffer a traumatic brain injury, resulting in 52,000 deaths, 275,000 hospitalizations and 80,000 cases of long-term disability.

"Although the prognosis for patients that are hospitalized with a severe form of TBI is generally not very promising, current research is pointing to a future of treatment that potentially offers these patients and their families hope for better quality of life.  In particular, two multi-center, Phase 3 clinical trials are worth noting.  They are BHR Pharma's SyNAPSe ( and Emory University's ProTECT III ( trials.  Both are evaluating the safety and effectiveness of progesterone as a neuroprotective agent for treating moderate to severe TBI.

"The success of these studies requires that study staff quickly reach family members to request permission to enroll their loved one in the trial. Although it may occur at a time of great personal pain and confusion, the families' difficult decision-making – usually in an emergency room setting – will go a long way in helping advance TBI treatment."


Back to top



Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
2. Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance
3. Octapharma Accepting Applications for Research Grants Through March 31
4. Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services
5. Possible pharmacological target(s) identified in pediatric OSA
6. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
7. Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010
8. Frost & Sullivan Ghanaian Pharmaceutical Industry Innovation & Advancement Award Conferred on LaGray Chemical Company
9. Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times
10. Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
11. Pharmalink Regulatory Affairs Consulting Firm Opens New Offices in Washington, DC and Hartford, CT
Post Your Comments:
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are ... Code Talker Award, an essay contest in which patients and their families pay tribute ... presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: